Area:
dopamine neuropharmacology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Justin T. Brown is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 2008 — 2010 |
Brown, Justin T |
R43Activity Code Description:
To support projects, limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s). R44Activity Code Description:
To support in - depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services. SBIR Phase II are considered 'Fast-Track' and do not require National Council Review. |
Rna Amplification For Diagnostic Microarrays @ Ambion Diagnostics, Inc.
DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and implement an integrated suite of technologies for enabling microarray-based diagnostic assays and the cGMP manufacturing processes and procedures necessary to manufacture these products. Microarrays have found widespread use in biology and medicine as important tools for evaluating gene expression and genomics. Using these tools, clinical researchers are driving the characterization of the molecular signatures of disease as they relate to both prognosis and therapy. By resolving the detection of complex analyte mixtures, microarray technology offers tremendous promise to improve patient care in situations in which clinical decisions must be informed by classifiers based on inputs from large sets of features. Broader implementation of diagnostic microarrays will require the development and manufacture of enabling technologies that are robust and reproducible and can be performed reliably and efficiently in the clinical diagnostic laboratory setting. Rigorous control of design and manufacturing processes of these products is essential to achieving inter-lot, inter-laboratory consistency and obtaining regulatory approval and reimbursement. The solutions to these issues should enable much more widespread implementation of diagnostic microarrays and the corresponding advances in human healthcare that are promised by molecular diagnostics. Phase I activities have resulted in the development of a cGMP manufactured, single-tube, streamlined amplification format that shows excellent correlation with industry- standard research-grade amplification reagents. This Phase II application outlines the steps we will take to expand features of this product to be the most comprehensive amplification format. The investigations in this grant will be directed toward the development of a thorough set of quality control features and assays that will give information suitability of the reagents for microarray outcomes. PUBLIC HEALTH RELEVANCE: As understanding of human disease progresses and new methods for high throughput analyses continue to be developed, molecular diagnostics testing is becoming more accurate but more complicated. Our investigations will provide quality and control tools to ensure that these diagnostic tests can be used in clinical laboratories.
|
0.903 |